Ascend Capital’s NovoCure NVCR Stock Holding History

Ascend Capital’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-654,152	Closed	-$13M	–	237
2017 Q3	$13M	Buy	+654,152	New	+$12.9M	0.49%	68

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

HCM

Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Ascend Capital's NVCR Position: Q4 2017 in Review

Ascend Capital sold out of NovoCure (NVCR) in Q4 2017, closing a stake of 654,152 shares — an estimated $13M sold.

Ascend Capital first reported a position in NVCR in Q3 2017 and held it in 1 quarter. The position peaked at $13M in Q3 2017. 128 funds tracked by Wall St. Rank hold NVCR as of Q4 2017.

Ascend Capital reported no remaining NovoCure position as of Q4 2017 after selling out during the quarter.
Ascend Capital sold 654,152 NovoCure shares in Q4 2017, an estimated $13M.
Ascend Capital first reported a position in NovoCure in Q3 2017 and held it in 1 quarter.
Ascend Capital's NovoCure position peaked at $13M in Q3 2017.
128 funds tracked by Wall St. Rank held NovoCure as of Q4 2017.

Based on Ascend Capital's 13F filing for Q4 2017, filed 13 Feb 2018.